Sprycel
Utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.
- Category
- Oncology Support
- Active ingredient
- Dasatinib
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 50mg
Sprycel details
- Therapeutic class
- Tyrosine Kinase Inhibitor
- Pharmacological class
- BCR-ABL Kinase Inhibitor
- Contraindications
- hypersensitivity to dasatinib
- Minor side effects
- diarrhoea; nausea; headache; fatigue
- Moderate side effects
- pleural effusion; haemorrhage; anaemia
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Bristol-Myers Squibb
- Onset Time
- variable
- Duration
- continuous
- Storage instructions
- Store at room temperature in original packaging.
- Drug interactions
- proton pump inhibitors; h2 antagonists
- Age restrictions
- Not recommended for children under 1 year.
Precautions and warnings
monitor for fluid retention; avoid strenuous activity if bleeding occurs; frequent monitoring of full blood count
Serious side effects
severe pulmonary hypertension, requires immediate medical attention; haemorrhage, requires immediate medical attention
Patient summary
utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.
Mechanism of action
Dasatinib is a multi-targeted kinase inhibitor that targets BCR-ABL, SRC family kinases, and other kinases to block the growth of Philadelphia chromosome-positive leukemic cells.
Pregnancy and breastfeeding
Pregnancy: Avoid conception; suspected foetal harm. Breastfeeding: Not recommended.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Sprycel
Sprycel contains the active ingredient dasatinib, used in the treatment of Chronic Myeloid Leukaemia and Acute Lymphoblastic Leukaemia. Manufactured by Bristol-Myers Squibb, this medication is supplied in a bottle containing 50mg strengths of dasatinib. Patients often recognize this treatment for its effectiveness in managing these conditions.
Sprycel availability in Asia
Sprycel is registered across 14 markets including Malaysia, the Philippines and Indonesia, with availability also in Taiwan, South Korea and Japan. While the original formulation remains a primary choice, generic dasatinib, often manufactured in India, provides significantly more affordable options for patients living without easy access to a pharmacy. Clinical use of this medicine is best managed under the direct supervision of a doctor.